- ►diabetesjournals.org KB Degn, CB Juhl, J Sturis, G Jakobsen, B Brock, V … - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for treating type 2
diabetes. We explored the effect of short-term (1 week) treatment with a GLP-1 derivative, liraglutide
(NN2211), on 24-h dynamics in glycemia and circulating free fatty acids, islet cell ... Cited by 170 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org S Madsbad, O Schmitz, J Ranstam, G Jakobsen, … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A double-blind, randomized, parallel-group,
placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients
with type 2 diabetes. The mean age was 56.6 years and the mean HbA 1c was 7.6% ... Cited by 170 - Related articles - BL Direct - All 6 versions
CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H Agersø, … - Diabetes, 2002 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential interest for the
treatment of type 2 diabetes. To evaluate actions of NN2211, a long-acting GLP-1 derivative,
we examined 11 patients with type 2 diabetes, age 59 ± 7 years (mean ± SD), BMI 28.9 ± ... Cited by 175 - Related articles - BL Direct - All 6 versions
- ►pubget.com [PDF] H Agersø, LB Jensen, B Elbrønd, P Rolan, M … - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like peptide-1 (GLP-1), a polypeptide hormone secreted by the
l-cells in the gastrointestinal tract, has shown promising effects as a new treatment modality for
patients with Type II (non-insulin-dependent) diabetes mellitus. However, the ... Cited by 168 - Related articles - BL Direct - All 5 versions
H Harder, L Nielsen, TDT Thi, A Astrup - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—After 8 weeks, liraglutide reduced fasting serum glucose (liraglutide, −1.90
mmol/l, and placebo, 0.27 mmol/l; P = 0.002) and HbA 1c (liraglutide, −0.33%, and placebo,
0.47%; P = 0.028) compared with placebo. No change in body weight was detected ( ... Cited by 90 - Related articles - BL Direct - All 7 versions
AM Chang, G Jakobsen, J Sturis, MJ Smith, CJ Bloem, … - Diabetes, 2003 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion in a glucose-dependent
manner, but its short half-life limits its therapeutic potential. We tested NN2211, a long-acting
GLP-1 derivative, in 10 subjects with type 2 diabetes (means ± SD: age 63 ± 8 years, BMI ... Cited by 94 - Related articles - BL Direct - All 9 versions
J Sturis, CF Gotfredsen, J Rømer, B Rolin, … - British journal of …, 2003 - pubmedcentral.nih.gov When liraglutide was dosed sc at 150 μg kg −1 bid for 6 weeks in ZDF rats 6–8 weeks of age
at study start, diabetes development was markedly attenuated. Blood glucose was approximately
12 mM lower compared to vehicle (P<0.0002), and plasma insulin was 2–3-fold higher ... Cited by 71 - Related articles - BL Direct - All 4 versions
- ►physiology.org B Rolin, MO Larsen, CF Gotfredsen, CF … - American Journal of …, 2002 - Am Physiological Soc NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1) derivative designed
for once daily administration in humans. NN2211 dose dependently reduced the glycemic levels
in ob/ob mice, with antihyperglycemic activity still evident 24 h postdose. Apart from an ... Cited by 130 - Related articles - BL Direct - All 4 versions
T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, O … - Diabetes Care, 2007 - Am Diabetes Assoc Main inclusion criteria were patients aged ≥18 years with type 2 diabetes and A1C ≥7.5 and
≤10.0% (diet) or ≥7.0 and ≤9.5% (mono–oral antidiabetes drug); previous therapy was
discontinued. Fasting plasma glucose (FPG) at randomization was 7–13 mmol/l. If FPG ... Cited by 117 - Related articles - BL Direct - All 5 versions
- ►endojournals.org B Ahren, M Landin-Olsson, PA Jansson, M … - Journal of Clinical …, 2004 - Endocrine Soc The stimulation of insulin vs. inhibition of glucagon secretion in relation to the antidiabetic action
of glucagon-like peptide-1 (GLP-1) is not established. Here, the influence of a 4-wk increase
in circulating GLP-1 by inhibition of dipeptidyl peptidase-4 (DPP-4) on 24-h glucose and ... Cited by 331 - Related articles - BL Direct - All 7 versions
